S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Improving clinical productivity in the academic setting: a novel incentive plan based on utility theory.
Madeline S. Wilson,Keith A. Joiner,Silvio E. Inzucchi,Gary J. Mulligan,Mary F. Mechem,Cary P. Gross,David L. Coleman +6 more
TL;DR: The unique threshold-based structure of the incentive plan, as determined through utility theory modeling, as well as permitting physicians to choose how to achieve the wRVU target were key features of its success, resulting in improved productivity without increasing practice resources or faculty salaries.
Journal ArticleDOI
Type 2 diabetes therapy. A pathophysiologically based approach.
TL;DR: The five classes of available oral antidiabetic agents are reviewed and their relationship to the pathophysiologic variables that contribute to hyperglycemia in type 2 diabetes is discussed.
Journal ArticleDOI
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF
Senthil Selvaraj,Zhuxuan Fu,Philip Jones,Lydia Coulter Kwee,Sheryl L. Windsor,Olga Ilkayeva,Christopher B. Newgard,Kenneth B. Margulies,Mansoor Husain,Silvio E. Inzucchi,Darren K. McGuire,Bertram Pitt,Benjamin M. Scirica,David E. Lanfear,Michael E. Nassif,Ali Javaheri,Robert J. Mentz,Mikhail Kosiborod,Svati H. Shah +18 more
TL;DR: Effect of dapagliflozin on key metabolic pathways, supporting a role for altered ketone and fatty acid biology with sodium-glucose cotransporter-2 inhibitors in patients with HFrEF, is observed.
Journal ArticleDOI
Noninvasive Assessment of the Diabetic Patient for Coronary Artery Disease
TL;DR: The cause of the macrovasculopathy of diabetes becomes apparent when one considers the deleterious effects of the hyperglycemic milieu, such as protein glycosylation, increased oxidative stress, endothelial dysfunction, and an underlying procoagulant state.
Journal ArticleDOI
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,David L. DeMets,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,John J.V. McMurray +13 more
TL;DR: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.